• Clinical and Experimental Pediatrics
• /
• 제64권4호
• /
• pp.157-164
• /
• 2021

Since the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in December 2019, a small number of coronavirus disease 2019 (COVID-19) cases in neonates have been reported worldwide. Neonates currently account for only a minor proportion of the pediatric population affected by COVID-19. Thus, data on the epidemiological and clinical features of COVID-19 in neonates are limited. Approximately 3% of neonates born to mothers with COVID-19 reportedly tested positive for SARS-CoV-2. Current limited data on neonates with COVID-19 suggest that neonatal COVID-19 shows a relatively benign course despite a high requirement for mechanical ventilation. However, neonates with pre-existing medical conditions and preterm infants appear to be at a higher risk of developing severe COVID-19. The greatest perinatal concern of the COVID-19 pandemic is the possibility of vertical transmission, especially transplacental transmission of SARS-CoV-2. Although direct evidence of the vertical transmission of SARS-CoV-2 is lacking, its possibility during late pregnancy cannot be ruled out. This review summarizes available case studies on COVID-19 in neonates and introduces what is currently known about neonatal COVID-19 with focus on its vertical transmission.

• Journal of Preventive Medicine and Public Health
• /
• 제53권2호
• /
• pp.67-69
• /
• 2020

Controversy remains over whether the coronavirus disease 2019 (COVID-19) virus may have infectivity during the incubation period before the onset of symptoms. The author had the opportunity to examine the infectivity of COVID-19 during the incubation period by conducting an epidemiological survey on a confirmed patient who had visited Jeju Island during the incubation period. The epidemiological findings support the claim that the COVID-19 virus does not have infectivity during the incubation period.

• Journal of Medicine and Life Science
• /
• 제17권2호
• /
• pp.33-40
• /
• 2020

Coronavirus disease 2019 (COVID-19) is a respiratory tract infection caused by a newly emergent coronavirus, that was first recognized in Wuhan, China, in December 2019. Genetic sequencing of the virus suggests that it is a beta coronavirus closely linked to the SARS virus. This disease has non-specific symptoms such as fever, dry cough, sore throat, and gastrointestinal symptoms. This virus can transmit via aerosol and need to droplet precaution to prevent spreading in public areas. Most people with COVID-19 develop only mild or uncomplicated illness. However, about 20% patients require hospitalization, oxygen supply, and intensive care. There is no currently effective treatment available for COVID-19 unresponsive to supportive care. This is review about the recently published epidemiologic, and clinical features, diagnosis, treatment and prevention of COVID-19.

• 한국융합학회논문지
• /
• 제11권9호
• /
• pp.7-13
• /
• 2020

최근 세계보건기구(WHO)의 Coronavirus Disease-19(COVID-19)에 대한 팬데믹 선언으로 COVID-19는 세계적인 관심사이며 많은 사망자가 속출하고 있다. 이를 극복하기 위하여 국가 간 정보 교환과 COVID-19 관련 대응 방안 등의 공유에 대한 필요성이 증대되고 있다. 하지만 언어적 경계로 인해 원활한 정보 교환 및 공유가 이루어지지 못하고 있는 실정이다. 이에 본 논문은 COVID-19 도메인에 특화 된 인공신경망 기반 기계번역(Neural Machine Translation(NMT)) 모델을 제안한다. 제안한 모델은 영어를 중심으로 프랑스어, 스페인어, 독일어, 이탈리아어, 러시아어, 중국어 지원이 가능한 Transformer 기반 양방향 모델이다. 실험결과 BLEU 점수를 기준으로 상용화 시스템과 비교하여 모든 언어 쌍에서 유의미한 높은 성능을 보였다.

• Korean Journal of Radiology
• /
• 제21권4호
• /
• pp.501-504
• /
• 2020

From December 2019, Coronavirus disease 2019 (COVID-19) pneumonia (formerly known as the 2019 novel Coronavirus [2019-nCoV]) broke out in Wuhan, China. In this study, we present serial CT findings in a 40-year-old female patient with COVID-19 pneumonia who presented with the symptoms of fever, chest tightness, and fatigue. She was diagnosed with COVID-19 infection confirmed by real-time reverse-transcriptase-polymerase chain reaction. CT showed rapidly progressing peripheral consolidations and ground-glass opacities in both lungs. After treatment, the lesions were shown to be almost absorbed leaving the fibrous lesions.

• Pediatric Infection and Vaccine
• /
• 제28권2호
• /
• pp.57-65
• /
• 2021

코로나바이러스감염증-19 (coronavirus disease 2019, COVID-19)의대유행 동안 이에 대응하기 위해 학교폐쇄가 이루어졌고, 이에 대해 경제학, 사회학, 수학모델링, 역학 및 공중보건을 포함한 다양한 학문분야에서 연구가 진행되고 있다. 인플루엔자 대유행의 모형으로부터 파생된 학교 폐쇄의 COVID-19에 대한 수리 모형은 상충되는 결과들을 보였다. 초기 연구에서는 학교와 지역사회 전반에 걸친 전파를 모델링하여 개학의 위험을 평가했으나, 이 위험이 성인 또는 소아의 전파 중 어떤 측면에 인한 것인지 여부는 여전히 불분명하다. 경험적인 결과들을 종합했을 때, 학교 폐쇄가 COVID-19 유행의 통제에 명확한 효과를 보여주지 못하였으며 이는 지역사회에 따라 COVID-19 유행의 규모가 다르고, 학교 폐쇄 정책이 다양하며, 여러 가지 대응 전략이 함께 사용되었기 때문일 수 있다. 학교 폐쇄의 이익은 불분명하고 정량화하기 어려운 반면, 학교 폐쇄에 따른 교육 격차 및 사회경제적 부담 등 미래 세대에 치러야 할 잠재적인 사회적 비용이 매우 커질 것이다. 본 종설에서는 COVID-19 대유행에 대응하기 위한 학교 폐쇄의 영향에 대해 정리하고 소아청소년의 건강 영향에 대한 고찰을 통해 교육기관 등교 정상화에 대한 제언을 하고자 하였다.

• Pediatric Infection and Vaccine
• /
• 제27권1호
• /
• pp.1-10
• /
• 2020

2019년 12월에 중국 후베이성 우한시에서 원인 미상 폐렴이 무리 지어 발생하기 시작하였다. 환자의 하기도에서 이전에 알려지지 않은 새로운 코로나바이러스가 분리되었으며 severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)로 명명되었다. 세계보건기구는 SARS-CoV-2에 의한 질병을 코로나바이러스감염증-19(coronavirus disease 2019, COVID-19)로 명명하였다. 2020년 3월 11일에 COVID-19는 전세계 최소 114국으로 퍼졌으며 약 4,000명이 사망하여 세계보건기구는 COVID-19가 세계적 대유행임을 선언하였다. 지난 20년 동안 새로운 코로나바이러스에 의한 두 번의 유행이 있었다. 2002-2003년 중증급성호흡기증후군(severe acute respiratory syndrome, SARS) 유행 시에는 8,098명의 확진 환자와 774명의 사망자가 발생하였으며, 2012년에 사우디 아라비아에서 시작되어 현재까지 주로 아라비아 반도에서 발생하고 있는 중동호흡기증후군(Middle East respiratory syndrome, MERS)는 2019년까지 총 2,499명의 환자와 858명의 사망자를 발생시켰다. 본 종설의 목적은 2020년 3월 12일까지 알려진 SARS-CoV-2의 특징과 전파 양상 및 COVID-19의 임상 증상을 알아보고 SARS와 MERS와의 유사점 및 차이점에 대하여 간략하게 소개하는 것이다.

• Tuberculosis and Respiratory Diseases
• /
• 제84권1호
• /
• pp.22-34
• /
• 2021

The coronavirus pandemic, known as coronavirus disease 2019 (COVID-19), is an infectious respiratory disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel coronavirus first identified in patients from Wuhan, China. Since December 2019, SARS-CoV-2 has spread swiftly around the world, infected more than 25 million people, and caused more than 800,000 deaths in 188 countries. Chronic respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD) appear to be risk factors for COVID-19, however, their prevalence remains controversial. In fact, studies in China reported lower rates of chronic respiratory conditions in patients with COVID-19 than in the general population, while the trend is reversed in the United States and Europe. Although the underlying molecular mechanisms of a possible interaction between COVID-19 and chronic respiratory diseases remain unknown, some observations can help to elucidate them. Indeed, physiological changes, immune response, or medications used against SARS-CoV-2 may have a greater impact on patients with chronic respiratory conditions already debilitated by chronic inflammation, dyspnea, and the use of immunosuppressant drugs like corticosteroids. In this review, we discuss importance and the impact of COVID-19 on asthma and COPD patients, the possible available treatments, and patient management during the pandemic.

• Journal of Microbiology and Biotechnology
• /
• 제30권3호
• /
• pp.313-324
• /
• 2020

Coronavirus disease 2019 (COVID-19), which causes serious respiratory illness such as pneumonia and lung failure, was first reported in Wuhan, the capital of Hubei, China. The etiological agent of COVID-19 has been confirmed as a novel coronavirus, now known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is most likely originated from zoonotic coronaviruses, like SARS-CoV, which emerged in 2002. Within a few months of the first report, SARS-CoV-2 had spread across China and worldwide, reaching a pandemic level. As COVID-19 has triggered enormous human casualties and serious economic loss posing global threat, an understanding of the ongoing situation and the development of strategies to contain the virus's spread are urgently needed. Currently, various diagnostic kits to test for COVID-19 are available and several repurposing therapeutics for COVID-19 have shown to be clinically effective. In addition, global institutions and companies have begun to develop vaccines for the prevention of COVID-19. Here, we review the current status of epidemiology, diagnosis, treatment, and vaccine development for COVID-19.

• Clinical and Experimental Pediatrics
• /
• 제63권4호
• /
• pp.119-124
• /
• 2020

A cluster of severe pneumonia of unknown etiology in Wuhan City, Hubei province in China emerged in December 2019. A novel coronavirus named severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) was isolated from lower respiratory tract sample as the causative agent. The current outbreak of infections with SARS-CoV-2 is termed Coronavirus Disease 2019 (COVID-19) by the World Health Organization (WHO). COVID-19 rapidly spread into at least 114 countries and killed more than 4,000 people by March 11 2020. WHO officially declared COVID-19 a pandemic on March 11, 2020. There have been 2 novel coronavirus outbreaks in the past 2 decades. The outbreak of severe acute respiratory syndrome (SARS) in 2002-2003 caused by SARS-CoV had a case fatality rate of around 10% (8,098 confirmed cases and 774 deaths), while Middle East respiratory syndrome (MERS) caused by MERS-CoV killed 861 people out of a total 2,502 confirmed cases between 2012 and 2019. The purpose of this review is to summarize known-to-date information about SARS-CoV-2, transmission of SARS-CoV-2, and clinical features.